Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Trump Says ExxonMobil Among Oil Majors Planning Venezuela Return 
South Korea Unveils Record $597 Billion 2027 Budget to Boost AI and Chips 
Trump Secures Drug Pricing Deals With Nine Pharma Companies 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
OpenAI Rejects Apple Trade Secret Theft Claims 
Shein Shares Slide 9% in Hong Kong IPO Debut 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Add as a preferred source on Google
JUPITER, Fla., March 15, 2018 -- Dyadic International, Inc. (“Dyadic”) (OTCQX:DYAI), today announced that Chief Financial Officer Thomas L. Dubinski
will be on a medical leave of absence, effectively immediately. In Mr. Dubinski’s absence, other executive officers will assume many of Mr. Dubinski’s duties while remaining in their current positions. Ping W. Rawson, the Company’s Director of Financial Reporting since June 2016, was promoted to Chief Accounting Officer on March 14, 2018 and will serve as the Company’s principal financial officer and assume responsibility for finance, tax and treasury.
About Dyadic International, Inc.
Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the fungus Myceliophthora thermophila, nicknamed C1. The C1 microorganism, which enables the development and large-scale manufacture of low cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines, monoclonal antibodies, biosimilars and/or biobetters, and other therapeutic proteins. Dyadic pursues research and development collaborations, licensing arrangements and other commercial opportunities with its partners and collaborators to leverage the value and benefits of using these technologies in the development and manufacture of biopharmaceuticals. In particular, as the aging population grows in developed and undeveloped countries, Dyadic believes the C1 technology may help bring biologic drugs to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers and, hopefully, improve access and cost to patients and the healthcare system, but most importantly save lives.
Please visit Dyadic’s website at www.dyadic.com for additional information, including details regarding Dyadic’s plans for its biopharmaceutical business.
Dyadic trades on the OTCQX tier of the OTC marketplace. Investors can find real-time quotes, market information and financial reports for Dyadic in the Company’s annual and quarterly reports which are filed with the OTC markets. Please visit the OTC markets website at www.otcmarkets.com/stock/DYAI/quote.
Contact:
Dyadic International, Inc.
Mark A. Emalfarb
Chief Executive Officer
Phone: 561-743-8333
Email: [email protected]
